Collaboration On Identification Of Microorganisms By MALDI-TOF Mass Spectrometry
The DSMZ is the German National Resource Centre for Biological Material, and currently stores and maintains approximately 14,000 cultures, representing 6,900 species from different types of microorganisms, including archaea, bacteria, yeasts and fungi. In the course of the planned collaboration, a comprehensive database will be generated that will include species and strains for many different application areas such as microbiological classification, clinical and diagnostic infectious disease research, as well as environmental analysis, food safety and water quality. The DSMZ will use the CLINPROT BioTyper for its internal quality control of strains, as well as for its on-going phylogenetic research in various microorganisms.
The DSMZ adopted the CLINPROT BioTyper technology for microorganism characterization due to the ability of MALDI-TOF mass spectrometry to identify large numbers of samples originating from complex mixtures of microorganisms, unequivocally and without the need for expert training. The convenient and cost-effective CLINPROT BioTyper sample preparation outperforms other approaches. Moreover, the CLINPROT BioTyper system includes an easy-to-operate bench-top MALDI-TOF with a small footprint that is well suited for operation in biological laboratories that are not mass spectrometry core facilities.
Prof. Dr. Erko Stackebrandt, Managing Director of DSMZ, pointed out: "There was an urgent need for a next- generation technique for the fast, convenient and cost-effective identification of microbial strains. Bruker Daltonik´s CLINPROT BioTyper is well suited for this purpose, as it fulfills these requirements. It has proven to be very robust and reproducible."
Dr. Wolfgang Pusch, Director of Clinical Proteomics and Biomarker Analysis, commented: "We are very pleased to have the DSMZ with their extraordinary expertise in microbiology as a strategic partner. This cooperation is a major step towards our goal of not only applying mass spectrometry in expert core facilities, but also making it available as a robust tool in routine biological analysis. The dual capabilities of our ClinProt MALDI-TOF systems for microorganism identification, as well as for tissue and body-fluid protein biomarker discovery, should be attractive for many clinical diagnostics research laboratories."
The CLINPROT BioTyper system will be introduced internationally at the Bruker Daltonics Pittcon booth #3155 in Orlando, Florida on March 13-16, 2006.
ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)
Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit http://www.bruker-biosciences.com
ABOUT DSMZ
The DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (German Collection of Microorganisms and Cell Cultures) is the most comprehensive biological resource center in Europe. With more than 14,000 microorganisms, 900 plant viruses, 550 human and animal cell lines, 500 plant cell cultures and more than 6,300 cultures deposited, the DSMZ has demonstrated its commitment to serve science for decades. Since 2004, the DSMZ is certified by DIN EN ISO 9001-2000. The DSMZ mission is 1) to collect, maintain and store biological material of relevance for applied biology, biotechnology, microbiology, teaching and other areas of research and general application, and 2) to perform collection-related research on these resources. The DSMZ is an independent, non-profit organisation. For more information, please visit http://www.dsmz.de
CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.
http://www.dsmz.de
http://www.bruker-biosciences.com
Colaborare pe identificarea de microorganisme de MALDI-TOF spectrometria de masã - Collaboration On Identification Of Microorganisms By MALDI-TOF Mass Spectrometry - articole medicale engleza - startsanatate